Meeting Impression: How to address residual risk post-ACS: LDL-c, dyslipidemia, and inflammationNews - Oct. 12, 2016
See below to download the Meeting Impression Despite optimal treatment for secondary prevention after an acute coronary syndrome (ACS), there is still a considerable residual risk burden. Beyond persisting high levels of cholesterol, inflammation and high triglyceride levels can contribute to this burden. It is therefore critical to not only develop medicines that can further lower LDL-c levels, but also to target the disease process in a multifactorial fashion. This can, for example, be achieved by targeting inflammatory pathways. During the ESC in Rome this year, the Physicians’ Academy for Cardiovascular Education (PACE) organised a satellite symposium in which residual risk targeting was discussed, including LDL-c-lowering approaches beyond statins and alternative approaches to target residual risk.
- Peter Libby, MD, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA (Chairman)
- Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
- Chris Packard, MD – University of Glasgow, United, Kingdom
- Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands
This satellite symposium was organised by the PACE Foundation and sponsored by unrestricted educational grants of MSD, Novartis Pharma AG and Amgen
Download Meeting Impression View lecture - Inflammation as potential target for therapy to target residual risk post ACS - by Dr. Paul Ridker View Lecture - Beyond statins: The role of ezetimibe in targeting residual - by dr Chris Packard